Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Corvus Pharmaceuticals, Inc. (CRVS)
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corvuspharma.com
Company Research
Source: GlobeNewswire
SITC presentation builds on data at ASCO in June, adding evidence supporting a new immuno-oncology approach with CPI-006 via activation of immune cells and the inhibition of adenosine production Company also presents data supporting potential of Adenosine Gene Signature to serve as a biomarker to identify patients that are likely to respond to CPI-006 and ciforadenant Company to host investor and analyst reception today at 6:00 pm ET BURLINGAME, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced updated results from its Phase 1/1b trial of CPI-006, the Company’s anti-CD73 antibody. The clinical data continue to support a novel mechanism of action involving the activation of immune cells potentially directed against tumors, along with the inhibition of a
Show less
Read more
Impact Snapshot
Event Time:
CRVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVS alerts
High impacting Corvus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRVS
News
- Insider Spends US$1m Buying More Shares In Corvus Pharmaceuticals [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $7.00 to $8.00. They now have an "outperform" rating on the stock.MarketBeat
- Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsGlobeNewswire
CRVS
Earnings
- 5/6/24 - In-Line
CRVS
Sec Filings
- 5/9/24 - Form SC
- 5/8/24 - Form 4
- 5/8/24 - Form 4
- CRVS's page on the SEC website